Electronic Capture of PROs in NCI Clinical Trials

Similar documents
Implementation of Electronic Capture of PROs in NCI Clinical Trials. Lori Minasian, MD, FACP Deputy Director, Division of Cancer Prevention, NCI

PRO ASSESSMENT IN CANCER TRIALS. Emiliano Calvo, Anita Margulies, Eric Raymond, Ian Tannock, Nadia Harbeck and Lonneke van de Poll-Franse

Patient-Centered Endpoints in Oncology

Cutting edge solution for patient adherence in clinical trials

MULTI-GROUP AUDITS, THE CENTRAL MONITORING PORTAL, AND OTHER CTSU UPDATES

CLOSING THE LOOP: Sharing Research Results with Participants

Road Home Program: Center for Veterans and Their Families at Rush. Philip Held, Ph.D. Research Director

Where We Are: NCI s Informed Consent Template and Updates to Address Changing Needs

PATIENTS REPORTED OUTCOMES IN ONCOLOGY PATIENT- CENTERED DRUG DEVELOPMENT: OPPORTUNITIES & CHALLENGES

Prostate Cancer Clinical Trials - PHEN s Rally Update and Next Steps

Sheila Prindiville, MD, MPH Director Coordinating Center for Clinical Trials National Cancer Institute

ISPOR European Congress Barcelona, Spain. November 14, 2018

Measuring Patient Health with PROMIS : Applications for Social Integration Research and Care

Distress Screening Playbook

Migrating a PRO Instrument. Presented by: Serge Bodart (Biomedical Systems) and Alisandra Johnson (Bracket)

For Protocol Amendment 5 of: RTOG 0938, A Randomized Phase II Trial of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer

Patient Reported Outcomes

The National Cancer Institute Community Oncology Research Program (NCORP) A Local Story

Patient Cloud. Future of Clinical Trials. and the. PhUSE Conference. Christopher Temme. October Product Management, Director

The Clinical Research E-News

Navigating Alliance Protocols

ISSUE BRIEF Conference on Clinical Cancer Research November 2011

National Cancer Institute Clinical Trial Cooperative Groups

National Cancer Institute

Impressions of a New NCI Director: Big Data

Prof Marion Eckert Rosemary Bryant AO Research Centre

PROPOSED WORK PROGRAMME FOR THE CLEARING-HOUSE MECHANISM IN SUPPORT OF THE STRATEGIC PLAN FOR BIODIVERSITY Note by the Executive Secretary

New Models of Evidence Generation and Cancer Care Delivery: Distance Medicine Technologies

Web-based epro: Validation, Equivalence, and Data Quality. Brian Tiplady

SEVENTH ANNUAL PATIENT-REPORTED OUTCOME (PRO) CONSORTIUM WORKSHOP. April 27-28, 2016 Silver Spring, MD

PRO-CTCAE PATIENT-REPORTED SYMPTOMATIC ADVERSE EVENTS. Lori Minasian, MD, FACP Deputy Director, Division of Cancer Prevention, NCI

DEVELOPMENTS IN THE CLINICAL TRIALS ENVIRONMENT Two Initiatives February 27, 2014

What is a Special Interest Group (SIG)?

Monday, September 11 Start Time End Time Session Type Product Focus Session name 8:00 am 12:00 pm Training Axys, APX APX/Axys Advanced Report Writer

PRO-CTCAE : PATIENT-REPORTED OUTCOMES VERSION OF CTCAE. Lori Minasian, MD Deputy Director, Division of Cancer Prevention, NCI

3.1.4 The phrase, and only focal nuclear, was clarified to and/or only focal nuclear.

Major Challenges in Danish Cancer Care

COVERAGE WITH EVIDENCE DEVELOPMENT

The Origins and Promise of PROMIS Patient Reported Outcomes Measurement Information System

NAVIFY Tumor Board NAVIFY

Methodological Considerations in Using Patient Reported Measures in Dialysis Clinics. Acknowledgements

Engaging with the new EU regulatory landscape for medical devices. Challenges and opportunities

GLOOKO DREAMED FOR ANDROID USER GUIDE

Cowen Investor Conference March confidently live life with ease

National Cancer Policy Forum Workshop on Multi-Center Phase 3 Clinical Trials and NCI Cooperative Groups

Clinical Trial Credentialing:

IROC Imaging and Radiation Oncology Quality Assurance for the NCTN

What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012

Patient Reported Outcomes: are they appropriate for clinical practice? Jose M Valderas Clinical Lecturer

The NIMH Data Repositories

Oncology Solutions Provider Training Program. Horizon NJ Health

Ministry of Children and Youth Services. Follow-up to VFM Section 3.01, 2013 Annual Report RECOMMENDATION STATUS OVERVIEW

Gavi, the Vaccine Alliance - Health System and Immunisation Strengthening (HSIS) Support Framework

SMARTPILOT FOR YPSOMATE: TRANSFORMING A PROVEN AUTOINJECTOR INTO A FULLY CONNECTED DEVICE

PANEL QUESTIONS FOR REGULATORY CONSIDERATION

UNITAID investments to innovate and scale up access to HIV diagnostics

MEASURES REGISTRY RESOURCES FOR MEASURING DIET AND PHYSICAL ACTIVITY

Population Health Research Institute. Who we are

Institute of Medicine Workshop: DIGITAL DATA PRIORITIES FOR CONTINUOUS LEARNING IN HEALTH AND HEALTH CARE

Update on the NCI Cancer Centers Program Henry P. Ciolino, Ph.D. Director, Office of Cancer Centers

TMIST: Frequently Asked Questions

Haliburton County Health Services Integration Transition Plan. June 25, 2014

Implementing PROMIS for Routine Screening in Ambulatory Cancer Care

International RT Clinical Trial Group Membership & Quality Control BY DR YING XIAO

510(k) submissions. Getting US FDA clearance for your device: Improving

NEUROSCIENCE TRIALS OF THE FUTURE: A WORKSHOP Pragmatic Trials: Challenges and Opportunities for Neuroscience Trials

Testing the measurement equivalence of electronically migrated patient-reported outcome (PRO) instruments: Challenges and Solutions

Using the NIH Collaboratory's and PCORnet's distributed data networks for clinical trials and observational research - A preview

The National Network of Depression Centers: Building a Virtual Learning Health System for Mood Disorders

Uses of the NIH Collaboratory Distributed Research Network

CDISC - Mapping New Pathways for Novartis. Darren Weston, Project Leader Pat Majcher, Senior Principal Programmer

HIT-Enabled Population Health Management. Tracey Moorhead July 19, 2010

The IFI has developed strategic objectives around three core activities:

MOBILE PATIENT-REPORTED OUTCOME (PRO) ASSESSMENT TO DRIVE ADHERENCE

Changing the Clinical Trials System: An NCI Update. Michigan Cancer Consortium Annual Meeting November 5, Marge Good, RN, MPH, OCN

CENTREPOINT DATA HUB REAL-WORLD INSIGHTS IN NEAR REAL TIME

A Framework for Optimal Cancer Care Pathways in Practice

Michael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation

The Academy Capitol Forum: Meet the Experts. Diagnosing Which Health Treatments Improve Outcomes: A PCORI Overview and How to Get Involved

Appendix N Pilot Program Question and Answer Version 5.0 6/23/2017

Appendix N Pilot Program Question and Answer Version 7.0 6/13/2018

2018 INFUSE CALL FOR INNOVATION

Note: This is an authorized excerpt from 2016 Healthcare Benchmarks: Digital Health To download the entire report, go to

USER GUIDE: NEW CIR APP. Technician User Guide

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation

Patient Reported Outcomes in Sickle Cell Disease. Marsha J. Treadwell, PhD 5 October 2016

2015 Exam Committees Report for the National Physical Therapy Examination Program

PIP Framework Information Session 10 April 2018

The South African approach to market conduct supervision - Treating Customers Fairly (TCF)

Convergence of Forces Driving Change in Today s Healthcare System

SWOG Plenary I Translational Medicine Science as the Foundation for Rapid and Meaningful Advances in Oncology

Adolescents to. Traditional methods applied in the dietary assessment of adolescents. Adolescence. Food records. 24 h recall

QUALITY IMPROVEMENT TOOLS

Taking Part in Cancer Treatment Research Studies

Alliance Organizational Structure. Trini Ajazi, MM Alliance Chief Administrative Officer Clinical Research Professional Orientation

Version for the Silent Procedure 29 April Agenda item January Hepatitis

ACUSON P500. Ultrasound Anytime, Anywhere. ACUSON P500. siemens.com/acusonp500. siemens.com/acusonp500 1

Report to the. GAVI Alliance Board June 2013

SECOND ANNUAL WORKSHOP ON CLINICAL OUTCOME ASSESSMENTS IN CANCER CLINICAL TRIALS

Outline. Mission. NCCIH Research Priorities HSR Community Conference September 11, National Center for Complementary and Integrative Health

Transcription:

Electronic Capture of PROs in NCI Clinical Trials Lori Minasian, MD, FACP Deputy Director, Division of Cancer Prevention, NCI July 27, 2017 Vision for PROs in NCI Clinical Trials Incorporate patient reported information into the study design to identify safe and effective interventions to treat, prevent and control cancer. Improve our ability to identify tolerable regimens Improve operational efficiency for the collection of PROs for investigators and site staff Streamline data collection and analysis with integration of PROs into the existing electronic data collection Improve the feasibility and usability of PRO collection to enhance patient participation 2 1

PRO Definitions HRQOL (Health Related Quality of Life) A multi-dimensional concept that includes domains related to physical, mental, emotional and social functioning. Purpose of measuring HRQOL is to determine the impact of the illness and its treatment on the well-being of the person. The aggregate effect PROs (Patient Reported Outcomes) Any report of the status of a patient s health condition directly from the patient. Focus on specific construct (symptom or function or other) Diary of hot flashes, dietary intake, or physical activity Response to specific question(s) related to pain or function, etc 3 HRQoL/PRO Should Inform the Primary Study Question What part of the patient experience helps understand the benefit/risk for this study? Functional outcomes, symptom burden, or overall HRQOL Data collected needs to reflect the clinical issue Time points for collection correspond to delivery of intervention and expected responses Disease outcomes are correlated with the PRO information Analysis plan for the HRQoL/PRO is in the statistical section with methods and sample size Summary score for HRQoL Symptom score or summary score for PRO 4 2

What HRQOL or PRO Tools Are Used in NCI Clinical Trials NCTN, NCORP have collected PROs for decades Using valid, reproducible, & reliable HRQOL Tools Usually compare aggregate effects between arms of study FACT (General, Disease Specific, Toxicity) commonly used EORTC Tools (QLQ C-30, EQ-5D) NIH Developed PROMIS Item Bank of Questions where the answers have been normed across different populations. Across disease areas, including some site specific cancers NCI Developed PRO-CTCAE 5 NCI s PRO-CTCAE Tool PRO-CTCAE is designed for patient reporting of symptomatic adverse events PRO-CTCAE is an item bank of questions Derived from the CTCAE adverse event items Complimentary to CTCAE (and to be used with) Incorporate into study design for patient reporting in similar timeframes for clinician reporting PRO-CTCAE is ONLY for descriptive reporting Framework for including PRO-CTCAE is AE reporting Not ready for clinical and protocol specific decision-making based upon individual PRO-CTCAE scores 6 3

Incorporation of PROs for NCTN, NCORP and ETCTN Incorporation of PROs Availability of PROs Inclusion of PROs NCTN/NCORP Long history of incorporating HRQoL into randomized trials HRQoL and PRO instruments curated into cadsr Pre-populated RAVE CRFs Standard PROs have been verified for electronic capture Review PROs in NCTN and NCORP trials for RAVE CRFs Confirm electronic capture is equivalent ETCTN Limited to no history of incorporating any PROs in early phase trials Interest from investigators to incorporate PROs PRO-CTCAE for symptomatic AEs Identify ETCTN trials to incorporate PRO-CTCAE Create RAVE Global PRO- CTCAE Library Development of data standards for PRO-CTCAE ongoing with FDA 7 Collection Methods for PROs Paper and pencil Long history of paper booklet collection Telephone Some Groups have central telephone collections IVRS useful Electronic Industry using electronic direct patient capture methods Increasingly being used, often with device provided by study RTOG has used VisionTree for electronic data collection (a few trials) ACRIN has used EASEEPRO for epro collection for COMET Alliance has begun work with Medidata epro Understanding the need for equitable selection of patients Flexibility for Multiple Modalities is key 8 4

Patient Cloud epro Overview What is Patient Cloud epro? A mobile app that collects patient responses to questionnaires / diaries and transfers data to the Medidata Clinical Cloud Set-up and execution with intuitive role-based user interface (patients do need email address) Fully integrated with Rave EDC to leverage the entire Medidata platform Available for Android and ios mobile devices 9 Patient Cloud epro Overview List of Instruments Patient Questionnaire PRO-CTCAE 10 5

NCI s epro Working Group Working Group Discussion Items Workflows Transition from use of Paper Source Documentation to epro. Define a process to record patients not filling out forms. Establish protocol template language for the inclusion of epro Establish informed consent template language for the use of epro Implementation Pilot Anticipate 10-15 trials for NCTN and NCORP Anticipate 4-5 trials for ETCTN 11 Data Standards for Electronic Collection of PROs Create a list of business needs/requirements for stakeholders on the inclusion of PROs. Data Management Centers Accrual Sites and staff Patients Evaluate the logistical features and operational aspects to inform the business rules Unique to collect data directly from patients into database without any filtering Compliance Monitoring for Quality Assurance Privacy Issues Consideration for monitoring patients response 12 6

Addressing Regulatory Issues of PROs in NCI clinical trials NCI and FDA have regular meetings exploring issues regarding PROs in cancer clinical trials Data standards meetings, Integrate regulatory requirements unique to electronic collection of information from patients Real time review of symptom severity Bring your own device (BYOD) Mixed modalities and quality control 13 Addressing Regulatory Issues of PROs in NCI clinical trials FDA, NCI and OHRP staff met in April 2017 to discuss the issue of patient reported severe findings Most patients on cancer clinical trials are followed closely Real-time monitoring? Not currently done with HRQOL and other PROs Usually reviewed and reported after trial completion Results not provided for individuals, but rather in aggregate Disclosure for patients as a reminder to need to contact your provider Acceptable Bring your own device NCI provides an opportunity to evaluate 14 7

epro and the NCI CIRB Already some trials sent to CIRB with electronic data capture of PROs Phase 3 trials from NRG using VisionTree (appendix for e-collection) COMET, the PRO correlative study exploring patients understanding of tumor profiling is using a different platform for electronic collection One concern is the handling of severe reports Real-time monitoring? Not now Disclosure for patients need to contact your provider Acceptable 15 Summary Electronic collection of patient-reported outcomes is becoming increasingly common NCI has invested in the electronic Patient Cloud within Medidata RAVE Platform consistent with the established electronic data collection for the networks within the NCI s shared infrastructure for clinical trials. Active ongoing work to understand the workflow process currently Determine the requirements for epro Facilitate the collection of PROs across all the Networks within the clinical trials shared infrastructure Understand the unique issues with data collected directly from patients and going into the database 16 8

NCI End Page www.cancer.gov www.cancer.gov/espanol 9